Another wave! The revised version of the "Biosecurity Act" introduced to the legislative agenda in the US Senate, but the suspense of "breaking through" still lingers.
①On the 23rd local time in the United States, the U.S. Senate will include Amendment S.3558 in the Senate legislative agenda by general order, confirming the new name of the bill, and there is unusual movement in the BrightGene system; ②Amendment S.3558 does not include the "grandfather clause" of the House version of the Biosecurity Act regarding exemptions, nor does it make any changes to the entities involved.
Humanwell healthcare's "autumn of many events": Controlling shareholder is being applied for reorganization, previously penalized by regulators | Speed Reading Notice
1. Tonight, humanwell healthcare announced that its controlling shareholder Contemporary Technology has applied for restructuring, which has been accepted, there is a possibility of a change in control of humanwell healthcare; 2. Humanwell healthcare, its controlling shareholder Contemporary Technology, and the actual controller have been repeatedly monitored and sanctioned by regulatory authorities; 3. Earlier this year, executives of humanwell healthcare have successively reduced their shareholding, and the 2024H1 performance continues the trend of 'increased revenue but not increased profit' from 2023.
"Miracle drug" for reducing fever – An Gong Niu Huang Wan and Zhangzhou Pientzehuang Pharmaceutical are being recalled in many places, causing a decline in market prices | Industry News
①The price of Angong Niuhuang Pills and Zinc Ingot of Zhangzhou Pientzehuang Pharmaceuticals has dropped, with a decrease of more than 100 yuan per pill/ingot. ②With the production and marketization of cultivated musk in the body, as well as the pilot project of lifting the ban on the import of natural musk in China, industry insiders expect that the tight supply and demand situation of musk raw materials will be alleviated.
Significant layoffs? Remegen responds: It is a normal business optimization. The recently adapted indication for Taitsip will be applied for listing.
①Regarding the online rumors of layoffs, the secretary of the board of directors of Remegen stated that the company has been sorting out its business since last year, and the optimization of positions and personnel is based on work needs, without a rigid proportion; ②The other party revealed that the severe myasthenia gravis indication of the targeted drug Taituxip is expected to apply for market approval soon. However, Taituxip is facing multiple competitions in the market.
Intends to acquire medical instruments dealer micro-tech for 0.29 billion, accelerating its overseas expansion.
①CME is a channel company for the sale of medical equipment products located in Europe, with sales advantages in products such as endoscopy. ②In recent years, to offset the domestic impact, micro-tech's overseas income has gradually increased, reaching 0.624 billion yuan in the first half of 2024, accounting for 46.78% of the overall income.
Listed companies have carried out intensive buybacks this week! Wuxi Apptec has launched its third round of 'cancellation-style' buyback plan this year, with a maximum repurchase amount of 0.1 billion yuan. Here is a list of A-share repurchase names.
①This week, the A-share listed companies continue to buy back stocks. According to incomplete statistics from Caixin, 11 listed companies plan to repurchase up to 0.1 billion yuan (see table); ②wuxi apptec, following the completion of the first two repurchase plans on February 5 and May 22, announced another 1 billion yuan repurchase plan on Tuesday evening. After the repurchase is completed, all repurchased shares will be cancelled and the registered capital will be reduced.